ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2119

Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies

Emma Mitchell1, Peter Lau2, Chloe Khoo2, Kortnye Smith2, Benjamin Brady2, Mark Shackleton2, Grant McArthur2, Ian Wicks1,3,4 and Shahneen Sandhu2, 1Rheumatology, Royal Melbourne Hospital, Melbourne, Australia, 2Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia, 3Medicine, University of Melbourne, Melbourne, Australia, 4Wicks Lab, Walter and Eliza Hall Institute, Melbourne, Australia

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Adverse events, cancer treatments and rheumatologic disease, Immunotherapy

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (anti-PD 1) antibodies, are established therapies for advanced malignancies, including melanoma, and non-small cell lung cancer (NSCLC). The adverse event (AE) profile of anti-PD 1 antibodies includes immune-related adverse events (irAEs) spanning several organ systems, many of which have defined management pathways. However, no consensus exists for the management of rheumatological (Rh) irAEs, including inflammatory arthritis, PMR and myositis, which affect 5-10% of patients receiving anti-PD 1 antibodies. Equally, there is a paucity of data presenting management options for flares of pre-existing rheumatic disease whilst undertaking anti-PD 1 therapy.

Methods:

We conducted a single centre retrospective study of patients treated with anti-PD 1 antibodies pembrolizumab (P) and nivolumab (N), who developed Rh irAEs, experienced flares of existing rheumatic disease, or experienced stability of existing rheumatic disease. Clinical and demographic data were obtained, including anti-PD 1 response (timing, durability and reason for cessation), rheumatologic presentation (including temporal relationship to anti-PD 1 therapy), rheumatologic treatment and response.

Results:

Eighteen patients (12 male, 6 female; median age 71.5 years) were included. All had metastatic malignancy (14 melanoma, 2 NSCLC, 2 head and neck squamous cell carcinoma). Anti-PD1 monotherapy (P or N) was used in 17 patients, 1 of whom had previously received the anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) antibody ipilimumab (I). One patient received combination N-I.

Thirteen patients developed de novo Rh irAEs (7 inflammatory arthritis, 1 PMR, 4 myositis, 1 fasciitis). Three experienced flare of Rh disease (all PMR). Two patients had no flare of their existing Rh disease (1 PMR, 1 with JIA/SSc). The median time to Rh irAE was 10.9 weeks (range 0.7-113). All myositis cases manifested within 4 weeks.

Twelve of the 16 irAEs required prednisone, all at doses ≥10mg/day. DMARDs were used in 5 cases, including HCQ in 4, MTX in 1, and SSZ in 1. One case received intravenous immunoglobulin.

Of the 18 patients, 7 completely responded to anti-PD 1, 7 partially responded, 3 had stable disease, and 1 progressive disease. Responses have been maintained despite Rheumatologic therapy. Median duration of response has not been reached.

Conclusion:

Rh irAEs to anti-PD 1 therapy present a new challenge for Rheumatologists and Oncologists. Both de novo disease, and flare, can occur. Our cohort demonstrated a high rate of response to anti-PD 1 therapy, including when Rheumatologic therapy was initiated. Prospective analysis is required to further characterise this set of diseases.


Disclosure: E. Mitchell, None; P. Lau, None; C. Khoo, None; K. Smith, None; B. Brady, None; M. Shackleton, None; G. McArthur, None; I. Wicks, None; S. Sandhu, None.

To cite this abstract in AMA style:

Mitchell E, Lau P, Khoo C, Smith K, Brady B, Shackleton M, McArthur G, Wicks I, Sandhu S. Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/rheumatological-immune-related-adverse-events-in-malignancy-patients-treated-with-anti-programmed-cell-death-pd-1-antibodies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatological-immune-related-adverse-events-in-malignancy-patients-treated-with-anti-programmed-cell-death-pd-1-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology